Practice code from the Food and Drug Administration should help to provide more reliable animal data, but will certainly not help to interpret this data. There is a lack of fundamental knowledge on the mechanisms of toxic compounds. If the mechanisms were known, choice of species, drug administration procedures and interpretation of results would be relatively easy and the animal data might then be appropriately extrapolated to man.
New antibiotics for therapeutic use in man or domestic animals may arise from the screening of new chemical compounds or from the screening of fermentation broths of bacterial or fungal cultures. In addition, they may arise from the synthetic modification of chemical nuclei such as the penicillins or cephalosporins, which are known to be potentially active as antibacterial agents and, moreover, are likely to have already a known mode of antibacterial action. It could be argued that predicting the likely activity in man of substances from the latter source could be done by purely in vitro methods. That this is not the case may be seen from a few examples.
In vitro activity New compounds are tested by a variety of techniques against pathogenic strains of bacteria in vitro, and from these something can be learned of the potential activity of the substances as antibiotics. Experience tells us that unless they have a certain minimal activity in vitro, for example a minimum inhibitory concentration of less than about 32 tg/ml, they have little chance of being effective antibacterial agents in vivo. Compounds less active than this, or those which have an inappropriate antibacterial spectrum or which have a spectrum and/or degree of activity already well covered by other acceptable antibiotics, are not progressed further. Further in vitro tests will establish if they are bactericidal or bacteriostatic in action, if they are affected adversely by serum protein or by other body tissues and if they are subject to inactivation by bacterial enzymes, such as beta-lactamases. But these tests will not tell us whether the compounds are likely to be acceptable antibioticsonly tests in vivo can take us a step nearer to that knowledge. These animal, in vivo, tests can be considered under three major categories: in vivo antibacterial activity, pharmacokinetic studies and toxicity testing.
In vivo antibacterial activity Many compounds, even those produced by modifying cephalosporins or penicillins, which appear to be very promising antibiotics in vitro, are found to be inactive or of very low activity when tested against experimental infections in animals. There may be one or more reasons for this. The pharmacokinetic properties may be wrong, the substance may be excessively bound to serum or tissue proteins, or it may be metabolized by body enzyme systems to an inactive or less active metabolite. It may also be too toxic to carry out a meaningful protection test. Since it is usually unknown beforehand which species of laboratory animal is likely to be closest to man in its handling of the new substance, and since it is necessary to test the antibiotic against several different microorganisms, protection tests have to be done on several species of animals, such as mice, rats and rabbits, experimentally infected with bacterial strains selected for their pathogenicity to the particular animal species. In addition, more specific tests may be done which may throw light on the activity of the antibiotic in specific situations in man; e.g. experimental urinary tract infections in rats, experimental respiratory tract infections in mice, experimental septicaemia and experimental meningitis in rabbits.
Protection tests of this nature can give a lot of information about an antibiotic's therapeutic quality in ways that are not immediately obvious. They may, for example, suggest specific indications for the antibiotic which would modify the doses, routes of administration and species of animal used in subsequent toxicity tests. Insofar as the tests may limit the uses of the antibiotic, this could save further animals. In addition, it is advisable to test the antibiotic against a number of strains in a given protection test. At first sight this may seem to be a waste of animals, but bacterial strains which behave in one way in vitro, e.g. with regard to betalactamase production, may behave differently in vivo. The results from a protection test against just one strain might indicate that the substance was worth progressing (and therefore using more animals), while testing against a range of strains might reveal the antibiotic's weaknesses and therefore lead to its early rejection. The in vivo protection tests therefore have to be done well and comprehensively on a sufficient number of animals to give statistically significant results.
Pharmacokinetic studies
Pharmacokinetic studies must be undertaken on laboratory animals for a number of reasons.
(1) It is necessary to determine the route -oral, intramuscular or intravenousby which the antibiotic is likely to be of value in man. If, for example, it can be absorbed only when injected, and not when given by mouth, further protection and toxicity tests by the oral route can largely be abandoned. (2) A knowledge of the blood-level time picture obtained in various animal species (mouse, rat, rabbit, dog) enables a reasonable prediction to be made of what the bloodlevel time picture is likely to be in man. It can be related also to the protecting activity in experimentally-infected animals, and some reasonably accurate predictions can be made about how active the antibiotic may be in naturally-occurring infections in man. The importance of these predictions cannot be overemphasized; upon them will depend whether the substance can be sent for clinical trial and what kinds of infection in man may respond to treatment. (3) A knowledge of how stable the antibiotic is in the body can be established by looking for metabolites. This may be important because the properties, antibacterial and pharmacokinetic, of the metabolite may be quite different from the substance that was administered. Cephalothin is a good example. Esterases, mostly in the liver, de-esterify the antibiotic with the production of a metabolite desacetylcephalothin. This has only about one-fifth the antibacterial activity of the parent substance. In such a case it becomes very important to establish whether the metabolism is the same in man as in animals. Mice and humans both deacetylate cephalothin but, whereas mice deacetylate cephalosporin C, man does not -a factor that can be related to the different protecting effect of the two antibiotics in the two species. (4) The route and speed with which the antibiotic is eliminated from the body must be studied also. Most of the beta-lactam antibiotics are eliminated by the kidney (by tubular secretion, by glomerular filtration or by both) but some, e.g. the carboxymethoxime cephalosporins, are excreted in significant amounts in the bileparticularly in small animals. Thus losses by this route are greatest in the mouse, less in rats, less still in rabbits and dogs. In this case only pharmacokinetic studies in man will give us a definite answer, but animal tests have indicated what to look for. There are some possible disadvantages to a very high rate of elimination via the liver and bile. If the antibiotic has a very broad antibacterial spectrum it may produce an imbalance in the intestinal flora with consequent undesirable side effects.
Many antibiotics are eliminated by the kidney and excreted in the urine. The rate of excretion must not be too rapid or the antibiotic will not have time to be effective. In general, in order to ensure adequate exposure time, the more rapid the excretion the more frequent the administration or the higher the dose required. The absolute amount of antibiotic collected in the urine (preferably 100% of unchanged material) will give valuable information about possible metabolism or excretion by other routes or inactivation by binding. Very occasionally an antibiotic is found which appears to have little or no means of elimination. A new polypeptide antibiotic, highly active against staphylococci resistant to many other antibiotics, was found recently which, upon injection, circulated for days on end (P W Muggleton & W F J Cuthbertson, personal communication). Protection could be obtained in mice when a challenge dose of staphylococci was preceded by a single dose of the antibiotic given more than 24 hours previously. The accumulation and toxic effects which might occur if repeated doses of such an antibiotic were given led to its rejection.
Toxicity testing Regardless of how effective an antibiotic might be in protecting animals against an experimental infection, it cannot be used if it is likely to be toxic. Such is the armamentarium of antibiotics now available to the physician that very high standards of acceptability must be met. In progressing a compound which looks promisingly effective in vitro and in vivo, it is usual to do preliminary tests in two species to eliminate quickly any highly toxic substance and to look for any specific target organs as the sites of toxicity. Obviously, whether it will be safe to proceed further with the compound will depend partly on the size of the ratio between the maximum dose producing no toxic effect and the dose producing a therapeutic effect, as revealed by the previous protection tests in animals. If this therapeutic ratio appears favourable, then further tests for possible toxicity must be done to progress the compound for administration to man. Often this progression occurs in three stages, the first of which is to clear the compound for the administration of single or a few repeat doses to human volunteers for pharmacokinetic studies. If the results of these studies are no good, the compound is rejected and the use of further laboratory animals is avoided. If the results are satisfactory, the second stage of much more extensive toxicity testing is undertaken, sufficient to clear the compound for limited clinical trial in patients. At this stage if full teratology studies have not been done, women of childbearing potential would be excluded from the trials. If these pilot, limited trials are satisfactory, full teratological and embryopathological studies will be done, together with any special toxicological investigations that may be necessary, such as determination of sensitizing potential and mutagenicity. Assuming all goes well and extended clinical trials indicate that we have an antibiotic worthy of introduction into medical use, i.e. the results indicate that it may do something new, better or more safely, still further animal testing may be required to satisfy the registration authoritiesthe requirements often differing from country to countrybefore a licence to sell the substance is given.
It would be impossible at present, or in the foreseeable future, to develop a new antibiotic without extensive animal testing. These experiments are costly and for this reason alone no antibiotic manufacturer would use animals unnecessarily. However, and more importantly, humane and ethical considerations dictate that neither unnecessary usage of animals nor suffering to those that are used would be countenanced.
Uses and limitations of primates in the evaluation of drug efficacy and safety A D Dayan MD FRCPath Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS In research and development of drugs for man and evaluation of their safety, it is striking how limited has been the contribution of experiments in nonhuman primates. The reasons for this have included discovery of appropriate physiological or pathological mechanisms on which to test compoundsfirst in more convenient laboratory animals, and often subsequently in
